Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $92.98, while State Street SPDR S&P Biotech ETF trades at $159.24. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | XBI | |
|---|---|---|
52-Week High | $97.99 | $164.28 |
52-Week Low | $92.76 | $86.92 |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $93.075 with a modest 0.34% daily gain, though technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF maintains consistent dividend distributions, with recent payouts of $0.31-$0.32 per share. Market sentiment is influenced by Treasury yield fluctuations and institutional positioning, with Bank of America increasing its stake by 69.8% in Q2 2026.
The outlook remains cautious as rising Treasury yields and inflation concerns pressure bond ETFs. Institutional accumulation provides support, but technical weakness and macroeconomic headwinds suggest limited near-term upside. Key risks include Fed rate policy uncertainty and oil price volatility affecting inflation expectations.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
